MeSH term
Frequency | Condition_Probility | Epithelial Cells/metabolism | 2 | 0.0 |
Female | 94 | 0.0 |
Hela Cells | 8 | 0.0 |
Humans | 187 | 0.0 |
Male | 100 | 0.0 |
Aged | 59 | 0.0 |
Biological Markers/blood | 4 | 0.0 |
Coronary Angiography | 14 | 6.0 |
Coronary Disease/blood/*diagnosis | 2 | 50.0 |
Exercise Test | 15 | 5.0 |
Middle Aged | 93 | 0.0 |
Natriuretic Peptide, Brain/*blood | 3 | 37.0 |
Prospective Studies | 7 | 0.0 |
Severity of Illness Index | 7 | 0.0 |
Thallium Radioisotopes/diagnostic use | 5 | 21.0 |
Tomography, Emission-Computed, Single-Photon | 5 | 9.0 |
Animals | 38 | 0.0 |
Apoptosis/*physiology | 4 | 0.0 |
Caspases/*metabolism | 9 | 4.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Enzyme Activation | 8 | 0.0 |
Mice | 21 | 0.0 |
Proteins/*metabolism | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 78 | 0.0 |
Adult | 54 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 35 | 0.0 |
Risk Assessment | 7 | 0.0 |
Graft Rejection | 2 | 1.0 |
Immunosuppression | 2 | 1.0 |
Parathyroid Hormone/blood | 2 | 1.0 |
Comparative Study | 28 | 0.0 |
Exercise Therapy | 2 | 12.0 |
Risk Factors | 41 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Postmenopause | 2 | 1.0 |
*Apoptosis | 8 | 0.0 |
Chromatin/metabolism | 2 | 0.0 |
DNA Fragmentation | 13 | 3.0 |
Models, Biological | 3 | 0.0 |
Protein Binding | 6 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Cross-Sectional Studies | 5 | 0.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Genotype | 4 | 0.0 |
Angiography | 4 | 9.0 |
Coronary Arteriosclerosis/*diagnosis | 2 | 50.0 |
Magnetic Resonance Angiography | 2 | 12.0 |
Sensitivity and Specificity | 11 | 0.0 |
Age Factors | 5 | 0.0 |
Aged, 80 and over | 16 | 0.0 |
Logistic Models | 6 | 0.0 |
Predictive Value of Tests | 12 | 0.0 |
Sex Factors | 7 | 0.0 |
Apoptosis | 4 | 0.0 |
Blotting, Western | 8 | 0.0 |
Caspases/metabolism | 7 | 1.0 |
Cell Line | 14 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Cell-Free System | 2 | 0.0 |
Protein Structure, Tertiary | 6 | 0.0 |
Time Factors | 6 | 0.0 |
Tumor Cells, Cultured | 11 | 0.0 |
False Positive Reactions | 3 | 1.0 |
Mammography/*methods | 2 | 50.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Base Sequence | 11 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Gene Expression Regulation | 3 | 0.0 |
Molecular Sequence Data | 18 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
DNA/*metabolism | 3 | 0.0 |
*DNA Fragmentation | 4 | 20.0 |
Enzyme Inhibitors/metabolism | 2 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Proteins/metabolism | 4 | 0.0 |
Aspartic Acid/*analogs & derivatives/pharmacology | 2 | 28.0 |
Drug Resistance | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Phosphonoacetic Acid/*analogs & derivatives/pharmacology | 2 | 40.0 |
Staurosporine/pharmacology | 4 | 2.0 |
Adolescent | 5 | 0.0 |
Child | 5 | 0.0 |
Comorbidity | 2 | 0.0 |
Diabetes Mellitus/epidemiology | 2 | 6.0 |
Prevalence | 8 | 0.0 |
United States/epidemiology | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Lipids/blood | 4 | 0.0 |
Seroepidemiologic Studies | 2 | 1.0 |
Child, Preschool | 2 | 0.0 |
English Abstract | 9 | 0.0 |
Follow-Up Studies | 7 | 0.0 |
Blood Glucose/analysis | 3 | 0.0 |
Body Mass Index | 3 | 0.0 |
Japan/epidemiology | 2 | 0.0 |
Lipoprotein(a)/blood | 2 | 3.0 |
Lipoproteins, HDL/blood | 3 | 1.0 |
Triglycerides/blood | 8 | 0.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
Organ Specificity | 3 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Coronary Disease/*blood | 5 | 7.0 |
Lipoproteins/*blood | 2 | 0.0 |
Prognosis | 13 | 0.0 |
Reproducibility of Results | 6 | 0.0 |
Case-Control Studies | 11 | 0.0 |
Coronary Disease/*diagnosis | 4 | 40.0 |
ROC Curve | 3 | 1.0 |
Apolipoproteins/*blood | 2 | 1.0 |
Multivariate Analysis | 3 | 0.0 |
Syndrome | 3 | 0.0 |
Dipyridamole/diagnostic use | 3 | 42.0 |
Exercise Test/*methods | 2 | 25.0 |
Radiopharmaceuticals/diagnostic use | 3 | 5.0 |
Technetium Tc 99m Sestamibi/diagnostic use | 3 | 20.0 |
Vasodilator Agents/diagnostic use | 2 | 20.0 |
Life Style | 5 | 3.0 |
Myocardial Infarction/etiology | 2 | 13.0 |
Lipoproteins, HDL Cholesterol/blood | 7 | 1.0 |
Lipoproteins, LDL Cholesterol/blood | 7 | 1.0 |
Regression Analysis | 3 | 0.0 |
Cytochrome c Group/metabolism | 2 | 1.0 |
In Vitro | 3 | 0.0 |
Odds Ratio | 3 | 0.0 |
Proportional Hazards Models | 4 | 0.0 |
Cohort Studies | 3 | 0.0 |
Coronary Disease/*radionuclide imaging | 2 | 40.0 |
Gated Blood-Pool Imaging | 2 | 40.0 |
Age of Onset | 3 | 0.0 |
Alleles | 4 | 0.0 |
Gene Frequency | 3 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Homocysteine/*blood | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Transfection | 4 | 0.0 |
Coronary Disease/*complications | 3 | 42.0 |
Etoposide/pharmacology | 2 | 1.0 |
HL-60 Cells | 2 | 0.0 |
CHO Cells | 3 | 0.0 |
DNA Damage | 2 | 0.0 |
Hamsters | 6 | 0.0 |
Electrocardiography | 10 | 3.0 |
Heart/*radionuclide imaging | 2 | 9.0 |
Thallium Radioisotopes/*diagnostic use | 2 | 20.0 |
Amino Acid Sequence | 12 | 0.0 |
Kinetics | 4 | 0.0 |
Proteins/chemistry/genetics/*metabolism | 2 | 2.0 |
Rats | 4 | 0.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
Sequence Homology, Amino Acid | 7 | 0.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Etoposide/toxicity | 2 | 11.0 |
Cholesterol/blood | 7 | 0.0 |
Homocysteine/blood | 3 | 2.0 |
Apoptosis/drug effects | 2 | 0.0 |
COS Cells | 2 | 0.0 |
Cloning, Molecular | 7 | 0.0 |
Heart Rate | 2 | 0.0 |
Deoxyribonucleases/metabolism | 2 | 11.0 |
Observer Variation | 2 | 1.0 |
Pregnancy | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Risk | 3 | 0.0 |
False Negative Reactions | 2 | 1.0 |
Retrospective Studies | 4 | 0.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Gene Expression | 3 | 0.0 |
Phenotype | 5 | 0.0 |
Deoxyribonucleases/*genetics | 3 | 75.0 |
Dinucleotide Repeats/*genetics | 2 | 8.0 |
Exons/genetics | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Survival Analysis | 5 | 0.0 |
Peptidyl-Dipeptidase A/*genetics | 2 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Jurkat Cells | 4 | 0.0 |
Proteins/*genetics | 3 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Reference Values | 4 | 0.0 |
Triglycerides/*blood | 2 | 0.0 |
Coronary Arteriosclerosis/*blood | 2 | 14.0 |
Chronic Disease | 2 | 0.0 |
Protein Precursors/*blood | 2 | 2.0 |
*Tomography, Emission-Computed, Single-Photon | 2 | 6.0 |
Deoxyribonucleases/*genetics/metabolism | 2 | 100.0 |
Alternative Splicing | 2 | 0.0 |
Deoxyribonucleases/chemistry/genetics/*metabolism | 2 | 100.0 |
Protein Isoforms | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Coronary Disease/*drug therapy | 3 | 18.0 |
Drug Therapy, Combination | 3 | 0.0 |
Myocardium/metabolism | 2 | 0.0 |
Minnesota/epidemiology | 2 | 18.0 |
Patient Selection | 2 | 1.0 |
*Caspases | 2 | 3.0 |
Plasminogen Activator Inhibitor 1/*genetics | 2 | 5.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Mutation | 3 | 0.0 |
Biological Markers | 3 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Aspartate Carbamoyltransferase/*genetics/metabolism | 2 | 66.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Analysis of Variance | 4 | 0.0 |
Double-Blind Method | 3 | 0.0 |
Safety | 2 | 1.0 |
Survival Rate | 3 | 0.0 |
*Coronary Artery Bypass | 3 | 4.0 |
Aspartate Carbamoyltransferase/genetics | 2 | 100.0 |
Dihydroorotase/genetics | 2 | 100.0 |
*Gene Amplification | 2 | 0.0 |
Infant | 2 | 0.0 |
Apoptosis/*genetics | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Blood Pressure/physiology | 2 | 1.0 |
Haplotypes | 2 | 0.0 |
Pedigree | 3 | 0.0 |
Coronary Disease/etiology | 2 | 5.0 |
Cause of Death | 2 | 1.0 |
Preoperative Care | 2 | 1.0 |
Evaluation Studies | 2 | 0.0 |
Coronary Disease/*physiopathology/radiography | 2 | 66.0 |
Exercise/*physiology | 2 | 0.0 |
Hemodynamic Processes | 4 | 2.0 |
Lipoproteins, LDL/blood | 2 | 0.0 |
Coronary Artery Bypass/*methods | 2 | 25.0 |
*Coronary Angiography | 3 | 13.0 |
Statistics | 2 | 0.0 |
Coronary Disease/diagnosis | 2 | 50.0 |
Methods | 2 | 0.0 |
Carbohydrate Sequence | 5 | 1.0 |
Molecular Structure | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Binding Sites | 3 | 0.0 |
Epitopes | 2 | 0.0 |
*Blood Group Antigens | 4 | 7.0 |
Carbohydrate Conformation | 3 | 2.0 |
Carbohydrates/analysis | 2 | 3.0 |
Erythrocytes/immunology | 2 | 0.0 |
Stroke Volume | 2 | 3.0 |
Lipids/*blood | 2 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Erythrocyte Membrane/*analysis | 2 | 9.0 |
Heart Catheterization | 3 | 4.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Erythrocyte Membrane/*immunology | 2 | 4.0 |
Lipoproteins, LDL Cholesterol | 2 | 8.0 |
Plasmids/metabolism | 2 | 0.0 |
Fibrinogen | 2 | 16.0 |
Phosphorylation | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Disease Progression | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Hemagglutination | 2 | 5.0 |
Feasibility Studies | 2 | 0.0 |
